SVP Corporate Development and Strategy, Aimmune Therapeutics
Mary Rozenman, PhD, is Senior Vice President of Corporate Development and Strategy at Aimmune Therapeutics. Prior to joining Aimmune in 2015, Dr. Rozenman was a Vice President at Longitude Capital, where she focused on mid-stage biotechnology investments and was an observer on Aimmune’s Board of Directors. Dr. Rozenman was previously a Junior Partner at McKinsey & Company and a leader in the Healthcare and Corporate Finance practices. At McKinsey, she advised senior management of leading pharmaceutical companies on a range of strategic and operational issues across marketing, sales, and clinical and corporate development. She also led McKinsey’s global Biosimilars practice. Dr. Rozenman holds a PhD in Organic Chemistry and Chemical Biology from Harvard University and a BA in Russian Literature and Biochemistry from Columbia University. Her scientific work has been published in premier scientific journals, including Nature, and she is a named inventor on several patents.